The latest trading day saw Pfizer (PFE) settling at $25.60, representing a -0.43% change from its previous close.

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Sponsored by the Indian Council of Social Science Research (ICSSR), the seminar served as a platform for experts, researchers, and students to discuss the role of artificial intelligence (AI) in ...

Núñez Feijóo, the leader of the Spanish People's Party (Partido Popular/EPP), the main opposition force in Parliament, met with Sánchez (PSOE/S&D) for talks on how the government intends to reach its ...

A 400-home neighbourhood at Hazelhurst Farm in Worsley, a site allocated in Greater Manchester’s Places for Everyone development plan, will go to committee for a decision next week.

This article has been corrected to reflect that the senators asked UpScriptHealth to respond. In August 2024, Pfizer Inc ...

In their own responses to the senators’ inquiries last fall, both Pfizer and Lilly emphasized the independence of their ...

Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...

In a year in which he faced down a challenge from an activist investor, Pfizer CEO Albert Bourla, Ph.D., received a 14% total ...

Pfizer has terminated a Phase I trial of its investigational STING therapy in advanced solid tumors, according to an update ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Arvinas (ARVN), 924% surge in interest Janux Therapeutics ...